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Abstract
Background: Despite advancements in the diagnosis and treatment of colorectal cancer (CRC), many patients die
because of tumor metastasis or recurrence. Therefore, identifying new prognostic markers and elucidating the
mechanisms of CRC metastasis and recurrence will help to improve the prognosis of the disease. As dysregulation
of microRNAs is strongly related to cancer progression, the aim of this study was to identify the role of miR-4775 in
the prognosis of CRC patients and the underling mechanisms involved in CRC progression.
Methods: qPCR and in situ hybridization were used to evaluate the expression of miR-4775 in 544 pairs of
paraffin-embedded normal and CRC tissues. Kaplan–Meier analysis with the log-rank test was used for survival
analyses. Immunohistochemical staining was applied to investigate the expression of miR-4775-regulated Smad7/
TGFβ pathway-associated markers. In vitro and in vivo invasion and metastasis assays were used to explore the
function of miR-4775 in the progression of CRC.
Results: miR-4775 was identified as a high-risk factor for CRC metastasis and recurrence, with high levels predicting
poor survival among the 544 studied CRC patients. Furthermore, high miR-4775 expression promoted the invasion
of CRC cells as well as metastasis and the epithelial to mesenchymal transition (EMT) via Smad7-mediated activation
of TGFβ signaling both in vitro and in vivo. Downregulating miR-4775 or overexpressing Smad7 reversed the
tumor-promoting roles of miR-4775/Smad7/TGFβ in vitro and in vivo.
Conclusion: miR-4775 promotes CRC metastasis and recurrence in a Smad7/TGFβ signaling-dependent manner,
providing a new therapeutic target for inhibiting the metastasis or recurrence of the disease.
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Background
Colorectal cancer (CRC) is the fourth leading cause of
cancer-related mortality worldwide [1], and tumor inva-
sion and metastasis are the main causes of mortality in
these patients [2]. During invasion and metastasis, acti-
vation of oncogenes and inactivation of suppressors play
significant roles [3]. Although many mechanisms under-
lying these processes have been elucidated and treatment
has improved, 50% of CRC patients still develop metas-
tases following surgery [4]. Therefore, identification of
new predictive markers and the mechanisms involved in
the invasion and metastasis of CRC is urgently needed.
MicroRNAs (miRNAs) are small non-coding RNAs
(18–24 nucleotides) that can exist stably in serum and
mediate biological processes such as tumor cell migra-
tion, invasion, proliferation and apoptosis [5]. Increasing
evidence has demonstrated that aberrant expression of
miRNAs can directly promote or inhibit CRC progres-
sion by degrading the 3′ untranslated regions (3′UTRs)
of target genes [6]. For example, miR-34a-5p suppresses
CRC metastasis via a p53-dependent pathway, and low
miR-34a-5p expression was found to predict good prog-
nosis in stage II/III CRC patients [3]. Through trans-
forming growth factor (TGFβ), miR-1269a directly
targets Smad7 and HOXD10, forming a positive feed-
back loop that enhances the metastatic capacity of CRC
cells [7]. In addition, miR-4775 has been verified as a
new onco-miRNA with a dual effect on the ERBB2/Her2
gene [8]. However, there are no reports to date on the
function of miR-4755 in CRC progression.
The Smad7 gene, also known as mothers against deca-
pentaplegic homolog 7 (MADH7), is located on human
chromosome 18q21.1 and encodes a protein of 426
amino acids [9]. Smad7-dependent activation of TGFβ
signaling is able to induce the epithelial to mesenchymal
transition (EMT) in CRC, allowing CRC cells to leave
the tissue parenchyma and enter systemic circulation,
followed by tumor invasion and metastasis [10]. Smad7 is
an inhibitory Smad protein that interacts with TGFβ type I
receptor, targeting it for proteasomal degradation and
thereby inhibiting TGFβ-I-induced phosphorylation of
Smad2/Smad3 [11]. Smad7 usually acts as a tumor suppres-
sor [12]. Indeed, it has been reported that Smad7 inhibits
breast cancer metastasis to the lung and liver, represses
melanoma cell metastasis to bone, and inhibits hepatocel-
lular carcinoma cell proliferation and invasion [13–15].
According to gene target prediction, a miR-4775 recogni-
tion sequence is present in the Smad7 3′UTR, though it
remains unclear whether miR-4775 promotes CRC metas-
tasis through activation of the Smad7/TGFβ pathway.
In this study, we verified the following: 1) miR-4775 is
more highly expressed in metastatic CRC tissues than in
non-metastatic tumor tissues; 2) high miR-4775 expression
predicts poor prognosis in CRC patients; 3) miR-4775
promotes CRC cell invasion, metastasis and EMT by
activating Smad7-dependent TGFβ signaling; and 4)
miR-4775-mediated Smad7/TGFβ activation predicts
poor survival in CRC patients. These data clarify the
role of miR-4775 in CRC progression and provide a
new marker for predicting CRC metastasis.
Methods
Patient tissue samples and tissue microarray construction
A total of 544 patients with CRC diagnosed at the De-
partment of General Surgery, Shanghai General Hospital,
School of Medicine, Shanghai Jiaotong University from
2005 to 2011 were enrolled. None of the patients re-
ceived anti-cancer treatment prior to tumor resection,
and those with advanced-stage disease received standard
postoperative 5-fluorouracil-based chemotherapy. Based
on their tumor recurrence status, we divided the 544 pa-
tients into tumor recurrence and non-recurrence groups
(Additional file 1: Table S1). Tissue samples were ob-
tained during operations. This research was approved by
the Ethics Committee of our hospital, and informed
consent was obtained from all patients before being
enrolled in the study. As previously reported, we con-
structed a tissue microarray that included samples from
these 544 patients [16].
Cell culture and transfection
We purchased CRC (SW480, HT-29, DLD-1, HCT116,
RKO, LoVo, HCT8, and SW62) and normal colon epi-
thelial (FHC) cell lines from the American Type Culture
Collection. All cell lines were tested by short tandem re-
peat analysis and used within 6 months; the last time of
authentication was February 2016. All cells were cultured
in Dulbecco’s modified Eagle’s medium (Gibco BRL, Grand
Island, NY, USA) containing 10% fetal bovine serum (FBS,
Invitrogen, Camarillo, CA, USA). Cells in which miR-4775
was either overexpressed or knocked down were generated
by transfecting miR-4775 mimics and anti-miR-4775
mimics, respectively. Smad7 was overexpressed or knocked
down by transfecting with lv-Smad7 or shRNA Smad7
plasmids, respectively. The empty vector and negative con-
trol (NC) vector were used as controls for miR-4775
mimics and anti-miR-4775 mimics, respectively. NC and a
scrambled vector were used as controls for the lv-Smad7
and sh-Smad7 vector, respectively. All overexpression and
knockdown sequences used in the study were the same as
those in a previous report [17].
qRT-PCR, in situ hybridization and western blotting
We performed a quantitative reverse transcription polymer-
ase chain reaction (qRT-PCR) assay, in situ hybridization,
and western blotting as described previously [13, 14, 18,
19]. U6 and GAPDH were used as internal controls. Anti-
body data are summarized in Additional file 2: Table S2.
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In vitro wound healing, migration and invasion assays
For the wound healing assay, we plated cells into six-
well plates and scraped the cells when they grew to
cover 90% of the surface. The cells were washed after
48 h, and the closed wound widths were then measured
and analyzed.
Matrigel invasion chambers (8.0 μm pore size, BD Bio-
sciences, Franklin Lakes, NJ, USA) and Transwell cell
migration plates were used for migration and invasion
assays. In total, 5 × 105 cells/ml were seeded in serum-
free medium in the upper chamber; 10% FBS was added
to the lower chamber. For the invasion assay, the Matrigel
coating was overlaid in the upper chamber. The cells were
incubated for 24 h and fixed, and 0.1% crystal violet was
used to stain the cells that adhered to the underside of the
membrane, which were counted under a light microscope
(Olympus Corporation, Center Valley, PA).
Immunofluorescence assay
Cells were incubated overnight in glass-bottom dishes,
washed three times with phosphate-buffered saline
(PBS), fixed with 4% paraformaldehyde for 15 min and
washed three times with PBS. The cells were then
permeabilized with 0.1% Triton X-100 for 10 min and
incubated overnight at 4 °C with primary antibodies
against E-cadherin, N-cadherin, and vimentin. After wash-
ing, Alexa Fluor 488-conjugated secondary antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) were added
for 2 h at room temperature. Nuclei were stained for
5 min with 4′,6-diamidino-2-phenylindole (DAPI; Roche,
Basel, Switzerland). A confocal laser-scanning microscope
(TCS SP8; Leica, Wetzlar, Germany) was used to collect
fluorescence images.
In vivo tumorigenesis in nude mice
To explore metastasis ability in vivo, cells overexpressing
or knocked down for miR-4775 and control cancer cells
(105/ml, 200 μl) were injected into the tail veins of nude
mice. All mice were sacrificed after 4 weeks. The tumor
colonies formed in the lungs and livers were observed
and counted under a microscope using hematoxylin-
eosin (HE) staining.
Statistical analysis
For categorical variables, either Fisher’s exact test or a
Chi-square test was used to compare differences. For
continuous variables, either Student’s t-test or one-way
analysis of variance was used to analyze differences.
Kaplan–Meier analyses with log-rank tests were used to
evaluate disease-free survival (DFS) and overall survival
(OS). The Cox proportional hazard model was applied
to estimate the hazard ratio and 95% confidence in-
tervals for DFS and OS. SPSS 22.0 statistical software
(SPSS Inc., Chicago, IL) was used for the data analysis. A
p value < 0.05 indicates a significant difference.
Results
Elevated miR-4775 is correlated with CRC progression and
indicates poor survival for CRC patients
To investigate the role of miR-4775 in CRC progression,
we performed qRT-PCR and in situ hybridization (ISH)
on 544 pairs of paraffin-embedded normal and CRC
tissues. We found that miR-4775 was significantly upreg-
ulated in CRC tissues compared to normal tissues
(Fig. 1a and e2). We then compared the expression level
of miR-4775 in CRC tissues at different stages and found
that levels gradually increased from stage I to stage IV
(Fig. 1b and e1–4). These analyses also showed that
miR-4775 was more highly expressed in the tumor re-
currence group than in the non-recurrence group
(Fig. 1c). More importantly, higher miR-4775 expression
was observed in patients with metastasis compared to
those without metastasis (Fig. 1d and e5–6). Taken to-
gether, these results indicate that miR-4775 has import-
ant functions in CRC tumorigenesis and metastasis.
Next, we examined the correlation between miR-4775
expression and TNM stage in 544 CRC patients. In total,
402 (73.90%) of CRC patient tissues showed high miR-
4775 expression (Additional file 3: Table S3), and high
miR-4775 expression was positively associated with T-
stage, lymph node metastasis, and distant metastasis
(Additional file 3: Table S3). These results further demon-
strate that upregulated miR-4775 promotes CRC progres-
sion and might play a significant role in the prognosis of
CRC patients.
Next, Kaplan–Meier analysis with the log-rank test
was used to evaluate the ability of miR-4775 to predict
survival in the 544 CRC patients. Patients with a high
level of miR-4775 showed lower DFS and OS rates than
those with a low level of miR-4775 (Fig. 2a and b). Inter-
estingly, no significant difference between high and low
miR-4775 expression was observed for OS in the non-
recurrence group (Fig. 2c), whereas high miR-4775 ex-
pression did predict poorer OS in the recurrence group
(Fig. 2d). Furthermore, multivariate Cox proportional
hazard analysis suggested that miR-4775 is an independ-
ent prognostic marker for tumor progression and metas-
tasis in CRC patients (Additional file 4: Table S4).
miR-4775 is involved in EMT and Smad7/TGFβ pathway
activation in CRC patients
EMT is an important process during cancer progression,
conferring epithelial cancer cells with increased invasive-
ness and motility [20]. During the EMT process, the can-
cer cell phenotype typically changes from epithelial to
mesenchymal, followed by upregulation of an epithelial
marker (E-cadherin) and downregulation of mesenchymal
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markers (e.g., N-cadherin, vimentin) [21]. Accordingly, we
employed immunohistochemical staining (IHC) to analyze
the expression of E-cadherin, N-cadherin, and vimentin in
tumor tissue from 544 CRC patients. The results showed
frequent co-incidence of low E-cadherin expression and
high N-cadherin and vimentin expression in tumor tissues
highly expressing miR-4775. Conversely, high expression
of E-cadherin and low expression of N-cadherin and
vimentin were generally found in tumor tissues of patients
with low levels of miR-4775 expression (Additional file 5:
Table S5, Fig. 3a and b). Pearson’s correlation analyses
based on IHC staining scores revealed a negative cor-
relation between miR-4775 and E-cadherin expression
(r = −0.4929, p < 0.001, Fig. 3c) but a positive associ-
ation between miR-4775 and N-cadherin (r = 0.5616,
P < 0.001, Fig. 3d) and vimentin (r = 0.4370, p < 0.001,
Fig. 3e) expression. These results show that miR-4775
expression is positively associated with EMT in CRC.
The Smad7/TGFβ pathway is involved in EMT and
CRC progression [17, 22, 23]. Thus, we further investi-
gated whether miR-4775 is positively correlated with ac-
tivation of Smad7/TGFβ signaling in CRC tissues. IHC
staining of the same patients’ tissues showed that high miR-
4775 expression was usually concomitant with weak Smad7
staining but strong p-Smad2 and p-Smad3 staining (Fig. 3f,
Additional file 6: Table S6); in contrast, low miR-4775
expression was often concomitant with strong Smad7
staining but weak p-Smad2 and p-Smad3 staining (Fig. 3g,
Additional file 6: Table S6). Furthermore, Pearson’s correl-
ation analysis revealed a negative correlation between miR-
Fig. 1 High expression of miR-4775 is correlated with tumor progression in CRC patients. a qRT-PCR analyses of miR-4775 expression in 544 pairs
of normal and CRC paraffin-embedded tissues (*p < 0.05). b Relative miR-4775 expression in stage I to stage IV tumor tissues (*p < 0.05, **p < 0.01,
***p < 0.001). c Relative miR-4775 expression in tumor recurrence and non-recurrence groups (*p < 0.05). d Relative miR-4775 expression in metastasis
and non-metastasis patients (*p < 0.05). e miR-4775 in situ hybridization (ISH) in a tissue microarray including 544 pairs of normal and tumor tissues. T,
tumor tissue; N, normal tissue; normal-LM, lymph node without tumor metastasis; M-LM, lymph node with tumor metastasis
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4775 expression and Smad7 staining but a positive correl-
ation with p-Smad2 and p-Smad3 staining in CRC tissues
(p < 0.05 for all, Fig. 3h–g). Taken together, these results
show that miR-4775 is not only involved in EMT but is also
correlated with Smad7/TGFβ pathway activation in the
progression of CRC.
miR-4775 promotes CRC cell invasion and metastasis
in vitro and in vivo
To explore the underlying biological mechanisms of
miR-4775 function in CRC progression, we evaluated
miR-4775 expression in 8 CRC cell lines and one normal
epithelial cell line (FHC). Among the 8 CRC cell lines,
SW620 and SW480 cells showed the highest and lowest
miR-4775 expression, respectively, compared with FHC
cells (Fig. 4a). Thus, we chose the SW480 and SW620
cell lines for further investigation and generated cells
overexpressing and knocked down for miR-4775, re-
spectively (Fig. 4b). A wound healing assay showed that
miR-4775 overexpression or knockdown promoted or
delayed wound closure, respectively, compared with the
respective control (p < 0.01 for both, Fig. 4c). In addition,
in vitro migration and invasion assays demonstrated that
miR-4775 overexpression or knockdown resulted in
higher or lower rates, respectively, of CRC cell migration
and invasion compared with the controls (p < 0.001 for
all, Fig. 4d and e). Consistent with these in vitro results,
overexpressing or knocking down miR-4775 expression
increased or decreased, respectively, lung and liver me-
tastasis in nude mice compared with the control groups
(p < 0.001 for all, Fig. 4f and g). Taken together, the re-
sults show that miR-4775 increases the invasion and
metastatic ability of CRC cells both in vitro and in vivo.
miR-4775 induces EMT in CRC
Interestingly, we also found that overexpressing miR-
4775 could induce cells to adopt a spindle-like fibroblas-
tic cell phenotype; in contrast, downregulating miR-4775
reversed this change (Fig. 5a). Thus, we hypothesized
that miR-4775 could induce CRC cells to undergo
EMT. qPCR and western blot assays showed that overex-
pressing or knocking down miR-4775 downregulated
Fig. 2 High miR-4775 expression predicts poor survival in CRC patients, especially for tumor recurrence patients. a Kaplan–Meier analysis with a
log-rank test for DFS in 544 CRC patients according to miR-4775 expression. b–d Kaplan–Meier analysis with a log-rank test for OS in all 544
patients (b) as well as non-recurrence (c) and recurrence groups (d). High miR-4775 predicts worse OS, especially in tumor recurrence patients
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or upregulated, respectively, E-cadherin expression
while upregulating or downregulating, respectively, N-
cadherin and vimentin mRNA and protein levels
(Fig. 5b and c). Immunofluorescence staining also re-
vealed that miR-4775 overexpression or knockdown
increased or decreased, respectively, E-cadherin ex-
pression and decreased or increased, respectively, N-
cadherin and vimentin expression (Fig. 5d). More im-
portantly, IHC staining of EMT markers in the xeno-
grafted tumors of nude mice further confirmed that
overexpressing or knocking down miR-4775 promoted
or inhibited, respectively, EMT in vivo (Fig. 5e). Col-
lectively, these results indicate that miR-4775 pro-
motes EMT in CRC cells in vivo.
Fig. 3 High miR-4775 expression is positively correlated with EMT and Smad7/TGFβ pathway activation in CRC patients. a–b Representative IHC
staining analyses of E-cadherin, N-cadherin, and vimentin in CRC tumor tissues with low or high miR-4775 expression (c–e). Spearman’s correlation
analyses showed that miR-4775 was negatively associated with E-cadherin expression but positively correlated with N-cadherin and vimentin
expression in 544 CRC tumor tissues (p < 0.001 for all). f–g Representative IHC staining of Smad7, p-Smad2 and p-Smad3 in pathologic serial
sections of CRC tumor tissues with low and high miR-4775 expression. h–j Spearman’s correlation analyses among miR-4775, Smad7, p-Smad2
and p-Smad3 H-scores in 544 CRC tumor tissues
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miR-4775 is a novel activator of the Smad7/TGFβ
pathway
To identify target genes of miR-4775, we performed bio-
informatics analysis with the public algorithm TargetS-
can7.0 (http://www.targetscan.org/). We screened cell
invasion-, metastasis- and EMT pathway-related genes
that have 3′UTRs containing the miR-4775-binding site,
and Smad7 was identified as a candidate (Fig. 6a). qPCR
analyses showed that overexpressing or knocking down
miR-4775 down- or upregulated Smad7 mRNA levels in
Fig. 4 miR-4775 promotes CRC cell invasion and metastasis in vitro and in vivo. a Relative miR-4775 expression in 8 CRC cell lines and one normal
colon epithelial line (FHC). b miR-4775 was overexpressed or knocked down by transfecting miR-4775 mimics or anti-miR-4775 vectors (***p < 0.001).
c–e Overexpression or knockdown of miR-4775 increased or decreased, respectively, CRC cell wound healing, migration and invasion abilities
in vitro (**p < 0.01,***p < 0.001). f–g CRC cells in lung and liver metastases in nude mice. Upregulation and downregulation of miR-4775 increased and
decreased, respectively, CRC lung and liver metastases in vivo (**p < 0.01, ***p < 0.001)
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SW480 or SW620 cells (Fig. 6b). Furthermore, a wild-
type Smad7 3′UTR luciferase reporter vector was con-
structed and transfected, and miR-4775 overexpression
or knockdown caused lower or higher Smad7 3′UTR lu-
ciferase activity, respectively (Fig. 6c). To demonstrate
whether miR-4775 directly promotes degradation of the
Smad7 3′UTR, we constructed luciferase reporter plas-
mids with a mutated Smad7 3′UTR and co-transfected
them with miR-4775, anti-miR-4775 and their corre-
sponding negative control vectors. The data shown in
Fig. 6c indicate that overexpressing miR-4775 decreased
luciferase activity in cells harboring the wild-type Smad7
3′UTR construct but not in cells carrying the mutant
Smad7 3′UTR (Fig. 6c). However, mutant miR-4775
could decrease the luciferase activity of the mutant
Smad7 3′UTR construct, whereas knocking down miR-
4775 expression increased the luciferase activity of the
wild-type Smad7 3′UTR but not that of the mutant
Smad7 3′UTR (Fig. 6d). These data suggest that miR-
4775 directly downregulates Smad7 expression by rec-
ognizing its 3′UTR. We further investigated whether
miR-4775 regulates TGFβ signaling by evaluating the
TGFβ/active-responsive SBE4-luc reporter and p3TP re-
porter activities. Overexpressing or knocking down ex-
pression of miR-4775 increased or decreased, respectively,
SBE4-luc reporter and p3TP reporter activities compared
with their control groups (Fig. 6e and f). Taken together,
these results further indicate that miR-4775 activates
Fig. 5 miR-4775 induces EMT in CRC. a The cell phenotype is significantly altered after transfection of miR-4775 mimics or anti-miR-4775 mimics
into SW480 or SW620, respectively, compared with their control groups (magnification × 200). b Fold changes in EMT marker mRNAs upon
miR-4775 overexpression or downregulation compared with their control groups (**p < 0.01, ***p < 0.001). c Western blotting analyses of EMT
markers in cells overexpressing or knocked down for miR-4775 and control cells. d Immunofluorescence staining analysis of EMT markers in cells
overexpressing or knocked down for miR-4775 and control cells. e IHC staining analysis of EMT markers in cells overexpressing or knocked down
for miR-4775 and their control subcutaneous xenograft tumors in nude mice (magnification × 200)
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the TGFβ pathway by directly downregulating Smad7
expression.
Subsequently, we found that overexpressing or knock-
ing down miR-4775 increased or decreased, respectively,
TGFβ R1, p-Smad2, p-Smad3 and MMP9 protein levels
and decreased or increased, respectively, the Smad7 pro-
tein level (Fig. 6g). Furthermore, overexpressing Smad7
partially reversed the increase in p-Smad2, p-Smad3 and
MMP9 protein levels caused by miR-4775 overexpres-
sion (Fig. 6h), whereas knocking down Smad7 partially
reversed the decreases in p-Smad2, p-Smad3 and MMP9
protein levels caused by miR-4775 downregulation
(Fig. 6i). Altogether, these results demonstrate that miR-
4775 activates the Smad7/TGFβ pathway in CRC cells.
Fig. 6 miR-4775 regulates the TGFβ pathway by directly repressing Smad7. a Potential miR-4775 binding sites in the Smad7 3′UTR and mutated
miR-4775 binding sites in the Smad7 3′UTR. b Smad7 mRNA changes upon miR-4775 overexpression or downregulation (**p < 0.01;***p < 0.001).
c–d Effects of miR-4775 overexpression or knock down on luciferase dual reporter activity with the wild-type and mutated Smad7 3′UTR. e p3TP
and f SBE4 reporter assay to analyze the roles of miR-4775 overexpression or knock down on activation of TGFβ signaling. g Western blot analyses
of Smad7/TGFβ pathway proteins after upregulation or downregulation of miR-4775 expression. h Effects of Smad7 overexpression on the protein
levels of TGFβ pathway-associated markers in miR-4775-overexpressing and control cells. i Effects of decreases in Smad7 on the protein levels of
TGFβ pathway-associated markers in cells knocked down for miR-4775 and the corresponding control group
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miR-4775 promotes the invasion and metastasis of CRC
cells by downregulating Smad7 in vitro and in vivo
Given the above effects of miR-4775 on the Smad7/
TGFβ pathway, we further investigated whether miR-
4775 could promote CRC invasion and metastasis by
directly degrading Smad7. We found that the effects of
overexpressing or knocking down miR-4775 on SW480
or SW620 cell wound healing, migration and invasion
Fig. 7 Roles of Smad7 in miR-4775-mediated tumor progression in vitro. a Overexpressing Smad7 partially weakened the promoting effect of miR-
4775 upregulation on SW480 cell wound healing, migration and invasion abilities compared with the control groups (*p < 0.05;**p < 0.01;***p < 0.001).
b Knocking down Smad7 partially inhibited the inhibitory effect of miR-4775 downregulation on SW620 cell wound healing, migration and invasion
abilities compared with the control group (*p < 0.05;**p < 0.01;***p < 0.001). c Overexpressing or knocking down Smad7 partially reversed the
effects of miR-4775 overexpression or knock down on the mRNA levels of EMT markers. d Overexpressing or knocking down Smad7 partially
reversed the effects of miR-4775 overexpression or knock down on the protein levels of EMT markers. e Immunofluorescence staining analysis
of EMT markers with regard to Smad7 overexpression or knockdown in cells with overexpressing or knocked down for miR-4775 and the
corresponding control cells
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were partially weakened or strengthened by overexpress-
ing or repressing Smad7 (Fig. 7a and b). With regard to
both mRNA and protein levels of EMT markers, overex-
pressing or knocking down Smad7 partially weakened or
restored, respectively, the downregulation or upregula-
tion of E-cadherin expression and the upregulation or
downregulation of N-cadherin and vimentin expression
caused by overexpressing or knocking down miR-4775
(Fig. 7c–e). These results suggest that miR-4775 pro-
motes CRC cell migration, invasion and EMT by degrad-
ing the Smad7 3′UTR in vitro.
Next, we injected these cells into the tail veins of nude
mice to evaluate whether miR-4775 enhances the meta-
static ability via Smad7 repression in vivo. We found
that overexpressing or knocking down Smad7 also par-
tially weakened or restored, respectively, the lung and
liver metastasis capacity resulting from overexpressing
or knocking down miR-4775 (Fig. 8a–d). Accordingly,
our in vitro and in vivo assays demonstrate that miR-
4775 increases the invasion and metastasis abilities of
CRC cells by downregulating Smad7.
Discussion
We found that miR-4775 was upregulated in CRC tissues,
predicting poor prognosis for CRC patients. Indeed, miR-
4775 overexpression promoted CRC cell invasion, metas-
tasis and EMT in vitro and in vivo, highlighting the
important role of miR-4775 in tumorigenesis and the
Fig. 8 Effects of Smad7 on miR-4775-mediated lung and liver metastases in nude mice. a–b Overexpressing or knocking down Smad7 inhibited
or promoted lung metastases caused by miR-4775 upregulation or downregulation in nude mice (***p < 0.001). c–d Overexpressing or knocking
down Smad7 decreased or increased the liver metastasis triggered by miR-4775 overexpression or knockdown in vivo (***p < 0.001)
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development of CRC. Furthermore, the present study veri-
fied that miR-4775 regulates Smad7/TGFβ pathway acti-
vation. The high risk of tumor recurrence and metastasis
suggests that CRC patients with high miR-4775 expression
and Smad7/TGFβ pathway activation should receive indi-
vidualized and more aggressive treatment after tumor
resection.
Although we have achieved a better understanding of
the genetic alterations in CRC in recent years, the prog-
nosis of CRC patients remains poor because of cancer
cell invasion and distant metastasis [24], which result
from the inherent heterogeneity and complex gene inter-
actions of CRC [25]. Accordingly, discovering new bio-
logical mechanisms and novel regulators of CRC will
provide a better approach for controlling CRC develop-
ment [4]. In the present, we identified miR-4775 as a
driver of CRC progression. These findings are consistent
with a previous report that miR-4775 acts as an onco-
miRNA and promotes breast cancer development via a
dual effect on the ERBB2/Her2 gene [8]. It is widely ac-
cepted that tumor invasion and metastasis are the main
driving forces of relapse [2], and herein, high miR-4775
expression was positively correlated with TNM stage.
Furthermore, the level of miR-4775 expression was
clearly higher in the tumor recurrence group than in the
non-recurrence group. Most importantly, high expres-
sion of miR-4775 predicted poor OS in the tumor recur-
rence group, though no such significant correlation was
found in the non-recurrent group. Overexpressing miR-
4775 increased CRC cell wound healing, migration and
invasion ability and enhanced CRC cell lung and liver
metastasis in nude mice. EMT has been widely reported
as a critical step in tumor invasion and metastasis [26].
For example, LncRNA-ATB was shown to induce hepa-
tocellular carcinoma EMT and invasion by competitively
binding to and inhibiting miR-200 family members and
then upregulating ZEB1 and ZEB2 [27]. We also verified
that overexpressing miR-4775 induces EMT in CRC
cells, with changes in cell morphology, upregulation of
the mesenchyme markers N-cadherin and vimentin, and
downregulation of the epithelial cell marker E-cadherin.
These findings further support our previous hypothesis
that miR-4775 promotes the progression and recurrence
of CRC in patients by increasing the invasive and meta-
static abilities of CRC cells.
TGFβ signaling is widely reported to be involved in
several biological processes, such as tumor cell growth,
apoptosis, adhesion, migration, and differentiation [28].
More importantly, in advanced stages of several epithe-
lial cancers, TGFβ functions as a potential activator of
cancer progression and metastasis by promoting EMT
[29]. TGFβ signaling is activated by the interaction of
heterodimeric transmembrane serine/threonine kinase
complexes, including type I (TGFβ RI) and type II
(TGFβ RII) receptors, with cytokines [30]. In the inacti-
vation process, Smad7 blocks R-Smad phosphorylation
by occupying the catalytic domain of TGFβ RI. Inhibit-
ing Smad7 leads to activation of R-Smads via phosphor-
ylation through TGFβ RI. Activated R-Smads (p-Smad2
and p-Samd3) form a complex with Smad4, which trans-
locates to the nucleus and regulates the transcription of
specific target genes [31]. In the present study, the pro-
moting function of high miR-4775 expression was weak-
ened by overexpression of Smad7, and high miR-4775
expression was generally found to be concomitant with
low Smad7 and high p-Smad2 and p-Smad3. Smad7
levels decreased and p-Smad2 and p-Smad3 levels in-
creased gradually with enhanced miR-4775 expression.
These findings indicate that the underlying mechanism
by which miR-4775 promotes CRC progression is related
to canonical activation of the Smad7/TGFβ pathway. In
addition, other miRNAs have been described as affecting
EMT in CRC by targeting the Smad7/TGFβ pathway, in-
cluding miR1269, miR224 and miR200c [7, 19, 26].
Nonetheless, it needs to be further explored whether
miR-4775 has synergistic effects with these reported
miRNAs on EMT in CRC and whether the impact of
miR-4775 is more important than that of these miRNAs.
Conclusions
In summary, our present study demonstrates the critical
roles of miR-4775 and the Smad7/TGFβ pathway in the
progression of CRC. Moreover, we identified a novel acti-
vation mechanism of the TGFβ pathway in CRC, provid-
ing a new treatment strategy for improving the prognosis
of these patients.
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